EYEN - CONSENSUS CO - Eyenovia, Inc.

Eyenovia, Inc. (EYEN) is developing contactless drug delivery technologies, leveraging the commercialization of Optejet and the success of Mydcombi. This chart of share prices on GURU.Markets reflects a level of . Growth potential is embedded in microdosing patents, which will ensure high returns following FDA approval. Meanwhile, management is currently revising its operating strategy to reduce biotech development costs.

This indicator aggregates the average expectations of institutional analysts regarding the fair value of assets, reflecting the revision of projected revenues for Eyenovia, Inc. (EYEN) based on the efficiency of external management of clinical trials and production. A decline in the average target price signals a systemic deterioration of the business's fundamental valuations, allowing investors to promptly identify recessionary trends and risks of market value loss.